Skip to content

Ciclosporin

Cequa, Neoral, Restasis, Restasis Multidose, Sandimmune, Verkazia, Ikervis (cyclosporine) is a protein pharmaceutical. Cyclosporine was first approved as Cequa on 1983-11-14. It is used to treat focal segmental glomerulosclerosis, myasthenia gravis, psoriasis, rheumatoid arthritis, and systemic lupus erythematosus in the USA. It has been approved in Europe to treat conjunctivitis, corneal diseases, and keratitis. The pharmaceutical is active against peptidyl-prolyl cis-trans isomerase A. In addition, it is known to target fMet-Leu-Phe receptor, sodium/bile acid cotransporter, solute carrier organic anion transporter family member 1B3, broad substrate specificity ATP-binding cassette transporter ABCG2, solute carrier organic anion transporter family member 1B1, and peptidyl-prolyl cis-trans isomerase D. Sandimmune's patents are valid until 2037-02-28 (FDA).
Trade Name Ikervis, Verkazia
Common Name Ciclosporin
Indication conjunctivitis, corneal diseases, focal segmental glomerulosclerosis, keratitis, myasthenia gravis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus
Drug Class Immunosuppressantcalcineurin inhibitoreye medication
Ciclosporin
Get full access now